BioAge Labs, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Conde nsed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2025 | 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(34,491) | $(26,573) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,178 | 2,410 |
| Depreciation expense | 95 | 82 |
| Loss on extinguishment of debt | — | 250 |
| Non-cash interest expense | 140 | 935 |
| Non-cash lease expense | 113 | 2 |
| (Gain) loss from changes in fair value on warrants | (48) | 78 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (603) | — |
| Prepaid expenses and other current assets | (1,045) | (1,621) |
| Other assets | 3 | (25) |
| Accounts payable | (550) | (1,211) |
| Accrued expenses and other current liabilities | (4,224) | (5,780) |
| Deferred revenue | (2,900) | — |
| Net cash used in operating activities | (37,332) | (31,453) |
| INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (585) | (35) |
| Purchases of marketable securities | (101,544) | — |
| Maturities of marketable securities | 8,500 | — |
| Net cash used in investing activities | (93,629) | (35) |
| FINANCING ACTIVITIES | ||
| Proceeds from Series D issuance | — | 170,000 |
| Issuance costs paid on Series D issuance | — | (542) |
| Term loan principal payments | (3,000) | (3,000) |
| Proceeds from issuance of common shares upon stock option exercises | — | 425 |
| Deferred offering costs | — | (1,269) |
| Net cash (used in) provided by financing activities | (3,000) | 165,614 |
| Effect of changes in exchange rate on cash and cash equivalents | (58) | 2 |
| Net (decrease) increase in cash and cash equivalents | (134,019) | 134,128 |
| Cash, cash equivalents and restricted cash at beginning of period | 354,349 | 24,957 |
| Cash and cash equivalents at end of period | $220,330 | $159,085 |
| Supplemental non-cash disclosure: | ||
| Conversion of convertible promissory notes into Series D-1 redeemable convertible preferred stock | $— | $40,651 |
| Purchases of property and equipment in accounts payable and accrued expenses | $18 | $— |
| Cash paid for interest | $393 | $810 |
| Right-of-use assets obtained in exchange for lease obligation | $3,106 | $282 |
| Deferred offering costs included in accounts payable, accrued expenses, and other current liabilities | $— | $1,328 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.